documents: FDA-2021-D-0691-0014

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2021-D-0691-0014 FDA FDA-2021-D-0691 Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer Guidance for Industry - Final Guidance Other Guidance 2022-12-06T05:00:00Z 2022 12 2022-12-06T05:00:00Z   2024-11-07T00:44:34Z   1 0 090000648550fc17

Links from other tables